US 11,998,544 B2
Methods of using splicing modulators
Ermira Pazolli, Wayland, MA (US); Silvia Buonamici, Boston, MA (US); James Palacino, Wellesley, MA (US); Michael Seiler, Belmont, MA (US); Ping Zhu, Acton, MA (US); Evan Barry, Milford, MA (US); and Lihua Yu, Acton, MA (US)
Assigned to EISAI R&D MANAGEMENT CO., LTD., Tokyo (JP)
Appl. No. 17/059,876
Filed by EISAI R&D MANAGEMENT CO., LTD., Tokyo (JP)
PCT Filed May 31, 2019, PCT No. PCT/US2019/034992
§ 371(c)(1), (2) Date Nov. 30, 2020,
PCT Pub. No. WO2019/232433, PCT Pub. Date Dec. 5, 2019.
Claims priority of provisional application 62/679,699, filed on Jun. 1, 2018.
Claims priority of provisional application 62/679,696, filed on Jun. 1, 2018.
Prior Publication US 2021/0346371 A1, Nov. 11, 2021
Int. Cl. A61K 31/496 (2006.01); A61K 35/17 (2015.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01)
CPC A61K 31/496 (2013.01) [A61K 35/17 (2013.01); A61K 38/191 (2013.01); A61K 38/2013 (2013.01); A61K 38/2066 (2013.01); A61K 38/208 (2013.01); A61K 38/2086 (2013.01); A61K 38/217 (2013.01); A61K 39/0011 (2013.01); A61K 39/39 (2013.01); A61K 39/3955 (2013.01); A61K 47/6803 (2017.08); A61K 2039/6031 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/6056 (2013.01); A61K 2039/6081 (2013.01)] 12 Claims
 
1. A method of treating a subject having or suspected of having a neoplastic disorder, comprising administering to the subject a therapeutically effective amount of Compound 1

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, and at least one additional therapy comprising a CTLA4 inhibitor, and wherein the neoplastic disorder is selected from myelodysplastic syndrome, chronic lymphocytic leukemia, acute lymphoblastic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, and colon cancer.